Ultragenyx selected as 2013 Fierce 15 Company
FierceBiotech selected Ultragenyx Pharmaceutical as one of the 2013 Fierce 15 Companies.
What makes Ultragenyx fierce: The most recent addition to the pipeline is KRN23, an antibody designed to treat rare cases of X-linked hypophosphatemia that is now wrapping a Phase I/II study at Kyowa Hakko Kirin. At the time KRN23 showed up on Ultragenyx’s radar, it was the only rare-disease program at the Japanese pharma company, says CEO Emil Kakkis. When the deal was done just days ago, it was Ultragenyx’s fourth midstage therapy.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.